Listed

Orthofix Medical Inc.: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 6, 2022 and accepted by EDGAR at May 6, 2022, 07:58 ET.

Share

Management's discussion and analysis

As filed, 22,058 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of Orthofix Medical Inc.’s (sometimes referred to as “we,” “us” or “our”) financial condition and results of our operations should be read in conjunction with the “Forward-Looking Statements” and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.

Executive Summary

We are a global medical device company with a spine and orthopedics focus. Our mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, our spine and orthopedic products are distributed in more than 60 countries via our sales representatives and distributors. For more information, please visit www.Orthofix.com (http://www.Orthofix.com).

Notable financial metrics and achievements in the first quarter of 2022 include the following:

  • Net sales of $106.4 million, an increase of 0.8% compared to the prior year on a reported basis and an increase of 2.0% on a constant currency basis
  • New product sales drive solid growth in Biologics, Spinal Implants, and Orthopedics
  • FDA grants PMA approval for AccelStim LIPUS bone growth stimulator, expanding our indications into fresh fracture care
  • FDA clearance received for the TrueLok Evo Ring Fixation system, which enables clear radiographic visualization

Results of Operations

The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:

Three Months Ended March 31, 2022 (%) 2021 (%)
Net sales 100.0 100.0
Cost of sales 26.6 24.5
Gross profit 73.4 75.5
Sales and marketing 50.9 48.1
General and administrative 18.2 15.6
Research and development 10.5 10.3
Acquisition-related amortization and remeasurement (3.3) 4.3
Operating loss (2.9) (2.8)
Net loss (4.2) (5.5)

Net Sales by Product Category and Reporting Segment

The following tables provide net sales by major product category by reporting segment:

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 Percentage Change Reported Constant Currency
Bone Growth Therapies $41,948 $42,947 -2.3% -2.3%
Spinal Implants 26,615 25,701 3.6% 4.2%
Biologics 14,092 13,692 2.9% 2.9%
Global Spine 82,655 82,340 0.4% 0.6%
Global Orthopedics 23,763 23,253 2.2% 7.2%
Net sales $106,418 $105,593 0.8% 2.0%

16

Global Spine

Global Spine offers the following products categories:

  • Bone Growth Therapies, which manufactures, distributes, sells, and provides support services for market leading devices that enhance bone fusion. Bone Growth Therapies uses distributors and sales representatives to sell its devices and provide associated services to hospitals, healthcare providers, and patients.
  • Spinal Implants, which designs, develops and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. Spinal Implants distributes its products globally through a network of distributors and sales representatives to sell spine products to hospitals and healthcare providers.
  • Biologics, which provides a portfolio of regenerative products and tissue forms that allow physicians to successfully treat a variety of spinal and orthopedic conditions. Biologics markets its tissues to hospitals and healthcare providers, primarily in the U.S., through a network of employed and independent sales representatives.

Three months ended March 31, 2022 compared to 2021

Net sales increased $0.3 million or 0.4%

  • Bone Growth Therapies net sales decreased $1.0 million or 2.3%, primarily driven by a slowdown in complex procedure volumes due to hospital restrictions and staff shortages, which impacted our ability to access both existing and prospective accounts
  • Spinal Implants net sales increased $0.9 million or 3.6%, driven by international spine fixation sales and continued growth in the U.S. for our M6-C artificial cervical disc
  • Biologics net sales increased $0.4 million or 2.9%, primarily attributable to sales from our new biologics offerings as we continue to broaden our Biologics portfolio

Global Orthopedics

Global Orthopedics offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions specifically related to limb reconstruction and deformity correction unrelated to the spine. Global Orthopedics distributes its products globally through a network of distributors and sales representatives to sell orthopedic products to hospitals and healthcare providers.

Three months ended March 31, 2022 compared to 2021

Net sales increased $0.5 million or 2.2%

  • Increase partially attributable to recovery in our international markets aided by lessening COVID-19 restrictions as well as an increase in orders from international stocking distributors
  • Continued strong contribution from our FITBONE limb-lengthening system
  • Partially offset by a decrease of $1.2 million due to changes in foreign currency exchange rates, which had a negative impact on net sales in 2022

Gross Profit

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
Net sales $106,418 $105,593 0.8%
Cost of sales 28,318 25,914 9.3%
Gross profit $78,100 $79,679 (2.0%)
Gross margin 73.4% 75.5% (2.1%)

Three months ended March 31, 2022 compared to 2021

Gross profit decreased $1.6 million

  • Decrease in gross profit is primarily driven by increased component costs resulting from global supply chain disruptions within our Bone Growth Therapies product category, unfavorable changes in our sales mix, and higher indirect operating expenses

Sales and Marketing Expense

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
Sales and marketing $54,137 $50,785 6.6%
As a percentage of net sales 50.9% 48.1% 2.8%

Three months ended March 31, 2022 compared to 2021

Sales and marketing expense increased $3.4 million

  • Increase primarily driven by increased marketing and professional fees, training expenses, travel expenses, and event spend compared to the prior year period
  • Increase also attributable to the hiring of additional sales and marketing headcount to support growth and initiatives across all product lines

General and Administrative Expense

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
General and administrative $19,328 $16,444 17.5%
As a percentage of net sales 18.2% 15.6% 2.6%

Three months ended March 31, 2022 compared to 2021

General and administrative expense increased $2.9 million

  • Increase in share-based compensation expense as the tenure of our new management team increases
  • Increase in spending on legal settlements, strategic investments, and medical benefits compared to the prior year period
  • Increase in travel and professional fees as a result of loosened COVID-19 restrictions as compared to the prior year period

Research and Development Expense

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
Research and development $11,212 $10,897 2.9%
As a percentage of net sales 10.5% 10.3% 0.2%

Three months ended March 31, 2022 compared to 2021

Research and development expense increased $0.3 million

  • Increase primarily driven by increases to support new product development, clinical studies, and costs associated with our European Union Medical Device Regulation compliance efforts

Acquisition-related Amortization and Remeasurement

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
Acquisition-related amortization and remeasurement $(3,499) $4,469 (178.3%)
As a percentage of net sales (3.3%) 4.3% (7.6%)

Acquisition-related amortization and remeasurement consists of (i) amortization related to intangible assets acquired through business combinations or asset acquisitions, (ii) the remeasurement of any related contingent consideration arrangement, and (iii) recognized costs associated with acquired in-process research and development assets, which are recognized immediately upon acquisition.

Three months ended March 31, 2022 compared to 2021

Acquisition-related amortization and remeasurement decreased $8.0 million

  • Decrease of $7.0 million primarily related to the remeasurement of potential future revenue-based milestone payments associated with the Spinal Kinetics acquisition that become due upon achievement of certain revenue targets
  • Decrease of $1.0 million in costs associated with acquired in-process research and development assets, which were recognized immediately upon acquisition in the prior year period

Non-operating Income and Expense

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
Interest expense, net $(375) $(417) (10.1%)
Other expense, net (936) (2,690) (65.2%)

Three months ended March 31, 2022 compared to 2021

Interest expense, net was flat in comparison to the prior year period

Other expense, net decreased $1.8 million

  • Decrease primarily associated with changes in foreign currency exchange rates and the resulting gains and/or losses recorded in each period

Income Taxes

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 % Change
Income tax (benefit) expense $71 $(207) (134.3%)
Effective tax rate (1.6%) 3.4% (5.0%)

Three months ended March 31, 2022 compared to 2021

Income tax expense increased an immaterial amount for the period ended March 31, 2022, compared to March 31, 2021.

The primary factors affecting our tax expense for the first quarter of 2022 were certain losses not benefitted.

Segment Review

Our business is managed through two reporting segments: Global Spine and Global Orthopedics. The primary metric used in managing the business by segment is EBITDA (which is described further in Note 10 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein). The following table presents EBITDA by segment and reconciles consolidated EBITDA to loss before income taxes:

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021
Global Spine $15,893 $11,895
Global Orthopedics (3,096) (2,229)
Corporate (9,295) (7,829)
Total EBITDA $3,502 $1,837
Depreciation and amortization (7,516) (7,443)
Interest expense, net (375) (417)
Loss before income taxes $(4,389) $(6,023)

Liquidity and Capital Resources

Cash and cash equivalents at March 31, 2022, totaled $71.9 million compared to $87.8 million at December 31, 2021.

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 Change
Net cash from operating activities $(7,709) $2,441 $(10,150)
Net cash from investing activities (5,667) (4,781) (886)
Net cash from financing activities (2,233) 1,110 (3,343)
Effect of exchange rate changes on cash (321) (534) 213
Net change in cash and cash equivalents $(15,930) $(1,764) $(14,166)

19

The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:

(U.S. Dollars, in thousands)

Three Months Ended March 31, 2022 2021 Change
Net cash from operating activities $(7,709) $2,441 $(10,150)
Capital expenditures (5,667) (4,781) (886)
Free cash flow $(13,376) $(2,340) $(11,036)

Operating Activities

Cash flows from operating activities decreased $10.2 million

  • Increase in net income of $1.4 million
  • Net decrease of $4.1 million for non-cash gains and losses, largely related to changes in fair value of contingent consideration, share-based compensation expense, deferred income taxes, and our provision for expected credit losses
  • Net decrease of $7.4 million relating to changes in working capital accounts, primarily attributable to changes in inventories

Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 61 days at March 31, 2022, compared to 59 days at March 31, 2021. Inventory turns remained consistent at 1.3 times as of March 31, 2022 and March 31, 2021.

Investing Activities

Cash flows from investing activities decreased $0.9 million

  • Decrease of $0.9 million associated with capital expenditures compared to the prior year period

Financing Activities

Cash flows from financing activities decreased $3.3 million

  • Decrease of $2.0 million related to the conclusion of the FITBONE Contract Manufacturing and Supply Agreement with Wittenstein
  • Decrease in net proceeds of $1.7 million from the issuance of common shares, primarily related to the exercise of stock options in the prior year period
  • Partially offset by an increase of $0.4 million attributable to other financing activities

Credit Facilities

As of March 31, 2022, we had no borrowings outstanding under our secured revolving credit facility. In addition, we had no borrowings outstanding under on our €5.5 million ($6.1 million) available lines of credit in Italy. We were in compliance with all required financial covenants as of March 31, 2022.

Other

For information regarding contingencies, see Note 7 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”)

In April 2020, we received $13.9 million in funds from the Centers for Medicare and Medicaid Service Accelerated and Advance Payment Program under the CARES Act. Starting in April 2021, Medicare began to recoup 25% of Medicare payments otherwise owed to the provider or supplier for submitted claims. Beginning in March 2022, recoupment increased to 50%, which will remain in effect for another six months. Thus, during this period, rather than receiving the full amount of payment for newly submitted claims, the Company’s outstanding accelerated / advance payment balance is reduced by the recoupment amount until the full balance has been repaid. As of March 31, 2022, the contract liability balance associated with the Accelerated and Advance Payment Program of the CARES Act totaled $1.4 million. The Company has classified the entire balance of this contract liability within other current liabilities based upon the Company’s estimates of when such funds will be recouped.

Spinal Kinetics Contingent Consideration

As part of the consideration for the Spinal Kinetics acquisition, we agreed to make contingent milestone payments of up to $60.0 million. One milestone payment, which was for $15.0 million, became due upon FDA approval of Spinal Kinetics’ M6-C artificial cervical disc (the “FDA Milestone”). The FDA Milestone was achieved and paid in 2019. A revenue-based milestone payment, totaling $15.0 million, was achieved and paid in 2021 upon meeting certain net sales targets.

The remaining milestone payment is a revenue-based milestone payment of $30.0 million in connection with future sales of the acquired artificial discs. The fair value of the contingent consideration arrangement as of March 31, 2022, was $11.7 million; however, the actual amount ultimately paid could be higher or lower than the fair value of the contingent consideration (ultimate payment will either be $30.0 million or the liability will be reversed if the milestone is not met within the required timeline). As of March 31, 2022, the remaining contingent consideration liability was classified within other current liabilities. For additional discussion of this matter, see Note 6 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

Neo Medical Convertible Loan

In October 2020, we entered into a Convertible Loan Agreement (the “Convertible Loan”) with Neo Medical SA, a privately held Swiss-based Medtech company (“Neo Medical”), whereby we loaned CHF 4.6 million ($5.0 million as of the issuance date) to Neo Medical. The loan bears interest at 8.0%, with interest due semi-annually. The Convertible Loan matures in October 2024; however, if a change in control of Neo Medical occurs prior to maturity, the Convertible Loan shall become immediately due upon such event.

Related Party Transaction

In February 2021, we entered into a technology assignment and royalty agreement with a medical device technology company partially owned and controlled by the wife of President and Chief Executive Officer, Jon Serbousek, whereby we acquired the intellectual property rights to certain assets for consideration of up to $10.0 million. Consideration was comprised of $1.0 million due at signing and $9.0 million in contingent consideration, dependent upon multiple milestones, such as receipt of 510(k) clearance or the attainment of certain net sales targets. None of the contingent consideration has been paid as of March 31, 2022.

IGEA S.p.A Exclusive License and Distribution Agreement

In April 2021, we entered into an Exclusive License and Distribution Agreement (the “License Agreement”) with IGEA S.p.A (“IGEA”), an Italian manufacturer and distributor of bone and cartilage stimulation systems. Per the terms of the License Agreement, we have the exclusive right to sell IGEA products in the U.S. and Canada. As consideration for the License Agreement, we agreed to pay up to $4.0 million, of which $0.5 million was paid in the second quarter of 2021, with certain payments contingent upon achieving an FDA milestone. The License Agreement also includes certain minimum purchase requirements.

Off-balance Sheet Arrangements

As of March 31, 2022, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.

Contractual Obligations

There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2021.

Critical Accounting Estimates

Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are detailed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no significant changes to our critical accounting estimates.

Recently Issued Accounting Pronouncements

See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements. As of March 31, 2022, we do not expect any of the issued Accounting Standards Updates to materially affect our condensed consolidated financial statements upon adoption.

Non-GAAP Financial Measures

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP metrics used to supplement information regarding the performance and underlying trends of our business operations to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

The non-GAAP financial measures used in this filing may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.

Constant Currency

Constant currency is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

EBITDA

EBITDA is a non-GAAP metric defined as earnings before interest income (expense), income taxes, depreciation, and amortization. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing the business.

Free Cash Flow

Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

Market risk

As filed, 123 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2021.

Controls and procedures

As filed, 1,481 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the President and Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2022.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, known to the President and Chief Executive Officer or the Chief Financial Officer that occurred for the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 1,823 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following risk factors supplement and should be read in conjunction with those contained in the risk factors disclosed in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2021, except as follows.

The conflict between Russia and Ukraine may continue to cause global economic instability and potentially disrupt supply chains.

In February 2022, Russia unlawfully invaded Ukraine, creating an ongoing humanitarian and global security crisis. In response, the U.S. and many other countries have imposed robust sanctions on Russia and may impose additional sanctions in the future. The ongoing invasion has caused significant damage and disruption to various aspects of the global economy. We have never conducted any meaningful business within Russia, and do not believe that the invasion will have material direct effects on our business or operations. However, we cannot predict the broader and longer-term consequences of this conflict or the sanctions imposed in response, and such consequences could include, among other things, general disruptions to global finance markets, exchange rates, and worldwide supply chains. Geopolitical instability and uncertainty resulting from the invasion could potentially have a negative impact on our ability to sell to, ship products to, collect payments from, and support customers in certain regions based on trade restrictions, embargoes and export control law restrictions, and logistics restrictions. These considerations could adversely affect our costs, risks, and efficiencies related to our supply chain and logistics. The potential effects of the conflict between Russia and Ukraine also could affect many of the other risk factors described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2021.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$106.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2022-01-01 to 2022-03-31$28.3mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2022-01-01 to 2022-03-31$78.1mus-gaap:GrossProfit
Research and development3 months2022-01-01 to 2022-03-31$11.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$3.1mus-gaap:OperatingIncomeLoss
Income tax3 months2022-01-01 to 2022-03-31$71.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-01-01 to 2022-03-31−$4.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-01-01 to 2022-03-31−$0.22us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-01-01 to 2022-03-31−$0.22us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-01-01 to 2022-03-3119,897,695 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2022-01-01 to 2022-03-31−$7.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$5.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$71.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$255.1mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$462.0mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$88.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$126.4mus-gaap:Liabilities
Shareholders' equityAt period end2022-03-31$335.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-007997. Last ingested by Listed: Nov 13, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.